Clinical Trial Search

Primary: Change in the Distance Transversed During the 6 Minute Walk Test From Baseline to Week 8. — -2.2 meters — p=1.000

Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] — 268; 370; 396; 615 nanogram*hour/milliliter (ng*hr/mL)

Primary: Change From Baseline on the National Eye Institute Corneal Staining Scale (NEI-CSS) at Week 4 — 0.23; 0.12; 0.26 Units on a scale

Primary: Change in Visceral Adipose Tissue Volume — -16; 19 cm2

Primary: Percentage of Participants With Improvement in Gout at 72 Hours Post-dose Using a Likert Scale — 100; 100 Percentage of participants

Primary: First Catheter Induced Complication — 78; 77 percentage of participants

Primary: Time to Loss of Consciousness of Patients Administered Anesthesia — 2.7 Minutes

Primary: Percentage of Correct Calls to Assess Reproducibility of the Spartan FRX CYP2C19 System. — 98.3; 100; 97.5; 99.2 Percentage of Correct Calls

Primary: Feasibility of EIT Monitoring in This Population of ARDS/ALI Patients — 13 Patients successfully monitored with EIT

Primary: Response Rate by Solid Tumor Response Criteria (RECIST) — 16 Percentage of Participants

Primary: Number of Participants Experiencing Recurrence of Atrial Fibrillation by One Year Follow-up — 20; 14 participants

Primary: Change in Hamilton Depression Rating Scale (HAM-D) Scores — -13.0; -11.0; -6.8 Change in HAM-D score

Primary: Clinical Laboratory Test: Haematology -Erythrocytes — -6.25; -5.2 erythrocytes counts x10000/μl

Primary: Objective Response Rate (Proportion of Patients With Objective Response) — 0.07 Proportion

Primary: Percentage of Participants Having an International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score Greater Than or Equal to 26 Through 12-Week…